Want to join the conversation?
Stifel Nicolas analyst Matt Sheerin questions $SNX on market share vs. managing the margins and managing profitability going forward. CFO Marshall Witt says that in prior quarters, performance was a little bit under market. In 2Q16, the company optimized its position and executed very well, but margin improvement is priority for the company.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?